



29th June 2016

Announcements

National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

iQN –IQX subsidiary acquires Novel Glucose Biosensor

iQX Ltd (NSX:IQX) iQX would like to announce that in partnership with IQNovate Ltd, and through their fully owned subsidiary; Life Science Biosensor Diagnostics Pty Ltd (LSBD), have acquired the Intellectual Property from the University of Newcastle and Newcastle Innovation Ltd, to a novel Glucose Biosensor.

This Biosensor is an Organic Thin Film Transistor (OTFT) platform that is capable of detecting a broad range of glucose levels, it is easy to use and cheap to manufacture.

LSBD will be, as soon as possible, implementing a clinical development program in order to generate efficacy and safety data that will allow for registration as a diagnostic system with the European Regulatory Authorities initially and then globally.

This biosensor platform enables blood glucose concentrations to be estimated by measuring the level of glucose in saliva and correlating the reading with the blood glucose level, hence obviating the need for diabetic patients to obtain a blood sample multiple times a day.

IQX CEO Dr. George Syrmalis was quoted stating “Successful commercialization of this biosensor means that millions of people worldwide will be able to monitor their blood glucose levels without the

pain of the needle prick several times a day. Hence we are focusing on bringing this to the market as soon as possible”

According to an industry report by Kalorama information it was estimated that the global glucose monitoring device and diabetes management market was valued in excess of US\$10 billion in 2015 .

Investor Relations

For further information, please contact:

iQ3Corp Investor Relations Team
Email: investor.relations@iq3corp.com
Phone: +61 2 8239 5400

About iQX Limited

iQX Limited is a specialist life science investment organization

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400
New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630
London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

Disclaimer

Subject to any continuing disclosure obligations under the laws of the Commonwealth of Australia or the NSX listing rules, iQX Ltd (iQX or the Company) disclaims any perceived intent or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. Expressions such as ‘believe’, ‘expect’, ‘anticipate’, ‘indicate’, ‘contemplate’, ‘target’, ‘plan’, ‘intends’, ‘continue’, ‘budget’, ‘estimate’, ‘may’, ‘will’, ‘schedule’ and similar expressions identify forward-looking statements.

The following cautionary statements qualify all forward-looking statements made in this announcement. In particular, the direction and strategies adopted by iQX and detailed in this announcement represents the Company’s strategic planning and decision-making practices and are based on current expectations. iQX’s business is subject to uncertainties, risks and contingencies, many of which are outside the control of, and are presently unknown to the Company, and could cause the actual conduct, results, performance or achievements of iQX to vary in a material way from those expressed or implied in this announcement. Investors are cautioned that forward-looking statements are not guarantees of future performance or outcomes, and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Additional information concerning iQX’s business, its associated risks and operations can be found in its periodic announcements to NSX.